Immune System News and Research

RSS

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

New combination clinical trial may improve outcome for cancer surgery patients

The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.

1 Feb 2012

Pneumonic plague bacteria transform lungs into a playground for microbes to flourish

Among medical mysteries baffling many infectious disease experts is exactly how the deadly pneumonic plague bacterium, Yersinia pestis, goes undetected in the first few day of lung infection, often until it's too late for medical treatment.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Study investigates trade-off between sperm quality and immunity

A new study shows the production of sperm is more biologically taxing than previously thought, and expending energy on it has significant health implications.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

Leprosy pathogen exploits micro-RNAs to weaken immune response

A team of UCLA scientists has found that the pathogen that causes leprosy has a remarkable ability to avoid the human immune system by inhibiting the antimicrobial responses important to our defenses.

30 Jan 2012

IGC researcher awarded ERC Advanced Grant for tissue damage study

There is more to fighting infection than just clearing the body of pathogens. As important as resisting infection, is limiting damage to the host's tissue caused, very frequently, by toxins produced by pathogens or by components of the host immune response that clears those pathogens.

30 Jan 2012

SENP1 prevents STAT5 from becoming trapped in nucleus

When SUMO grips STAT5, a protein that activates genes, it blocks the healthy embryonic development of immune B cells and T cells unless its nemesis breaks the hold, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

30 Jan 2012

Researchers identify dual role of key player in human immune system

Northwestern University Feinberg School of Medicine researchers have identified a new and unusual role for a key player in the human immune system. A protein initially believed to regulate one routine function within the cell has proven vital for another critical step in the activation of the immune system.

30 Jan 2012

HPV transmission via oral sex practices suggests research

A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.

29 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

Researchers discover new gene linked to MLCRD

Researchers have found a new gene that, when mutated, can lead to lymphoedema (swollen limbs) as part of a rare disorder that can also cause problems with eye and brain development. This is the fourth lymphoedema-related gene found by the same researchers in three years, and the first linked to the eyes and brain. They say it could lead to better diagnosis and treatment for lymphoedema, an area that has been poorly understood previously.

27 Jan 2012

Celgene signs definitive merger agreement to acquire Avila

Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.

26 Jan 2012

Chemicals in packaged food and textiles linked to low immunity in kids: Study

According to researchers children exposed to chemicals from food packaging and textile products may have compromised immune systems. They found kids with more perfluorinated compounds, or PFCs, in their blood stream were less likely to respond to routine vaccines.

26 Jan 2012

Seattle Children's receives $5M gift from Ben Towne for pediatric cancer study

Seattle Children's Research Institute today announced a $5 million gift from Ben Towne Pediatric Cancer Research Foundation. The funding will be used to accelerate the work of Michael Jensen, MD, and his Seattle Children's Research Institute team who are creating new cancer treatments that reprogram a child's immune system to attack and kill cancer cells with the goal of minimizing or even eliminating the need for chemotherapy or radiation.

25 Jan 2012

Sofie to receive U.S. patent for novel PET probes

Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

25 Jan 2012